Hyperfine, Inc.

Hyperfine, Inc.

NNASDAQ:HYPR
0.61
USD
-0.02
(-3.05%)
-0.30EPS
85.81MMarket Cap
Mar 24Next Earn
Hyperfine, Inc.
NASDAQ:HYPR
(Nasdaq Stock Market)

Recent

price

0.61

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
0.02
0.1
0.15
0.18
0.17
0.19
Revenue per Share
-0.28
-0.33
-0.92
-1.04
-0.62
-0.56
-0.43
-0.3
Basic EPS, GAAP
-0.27
-0.33
-0.71
-1.04
-0.6
-0.54
-0.36
-0.28
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.57
-0.87
2.65
1.75
1.17
0.67
0.42
0.3
Book Value per Share
-0.57
-0.87
2.65
1.75
1.17
0.67
0.42
0.3
Tangible Book Value per Share
70
70
70
70
71
72
82
99
Basic Weighted Avg Shares
- -
- -
1
7
11
13
14
19
Sales/Revenue/Turnover
- -
-7,990.14
-4,336.1
-1,084.15
-436.14
-335.33
-273.43
-167.64
Operating Margin (%)
- -
- -
1
1
1
1
1
1
Depreciation Expense
-19
-23
-65
-73
-44
-41
-36
-30
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-7,968.37
-4,334.96
-1,073.73
-401
-315.9
-262.29
-156.42
Profit Margin (%)
26
64
182
120
80
45
39
43
Working Capital
- -
- -
- -
- -
- -
- -
- -
13
LT Debt
-40
-61
186
124
84
49
41
32
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-47.21
-42.51
-61.03
-79.01
-101.73
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
- -
- -
- -
LT Borrowings
13
13
13
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
99
106
106
Market Capitalization
106
143
86

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
56
59
54
Cash, Cash Equivalents & STI
41
43
38
Accounts Receivable, Net
4
4
5
Inventories
6
7
6
Total Current Liabilities
10
10
11
Payables & Accruals
7
5
5
ST Debt
- -
- -
- -
Deferred Revenue
2
3
3

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-105.73%
-16.38%
Free Cash Flow
- -
17.38%
-25.59%
Net Income, GAAP
- -
25.9%
-12.64%
Sales/Revenue/Turnover
- -
169.66%
5.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3
4
4
2
13
2025
2
3
3
5
14
2026
4
4
6
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.14
-0.14
-0.14
-0.14
-0.56
2025
-0.12
-0.12
-0.14
-0.06
-0.43
2026
-0.09
-0.09
-0.06
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Hyperfine, Inc. (Nasdaq: HYPR) develops, manufactures, and commercializes portable magnetic resonance imaging (MRI) systems for point-of-care brain imaging; its flagship Swoop Portable MR Imaging System, powered by Optive AI software, operates at ultra-low field strength (0.064T) to produce diagnostic-quality images including T1, T2, FLAIR, and DWI sequences in axial, coronal, and sagittal planes without requiring specialized infrastructure or shielding; the company also provides Hyperfine Image Viewer cloud platform for image archiving and management, technical support services, and software updates. Founded in 2014 by Jonathan Rothberg and headquartered in Guilford, Connecticut, Hyperfine targets hospitals (ICUs, emergency departments, neurology), clinics, pediatrics, stroke centers, and research institutions with its wheeled, AI-enhanced systems that enable bedside scanning globally. In 2025, Hyperfine secured FDA clearance and launched commercial sales of its next-generation Swoop system with Optive AI for substantially improved image quality; introduced the PULSE platform to accelerate AI-powered MRI adoption; announced first patient enrollments in PRIME, PRISM PMR, and NEURO PMR clinical studies evaluating portable MRI in emergency departments, operating rooms, and neurology offices; received a $3.7 million grant for global brain health initiatives and a CE Mark/UKCA approval for Optive AI to expand in Europe; expanded distribution partnerships in Turkey, Israel, Saudi Arabia, India, and additional European/Middle Eastern markets; and completed $17.5 million and $6.0 million offerings to support commercialization, manufacturing, and R&D.

Company News

  • Hyperfine, Inc. (HYPR) Q3 2026 Earnings Call Transcript

  • What Hyperfine (HYPR) Said on Its Q3 Earnings Call

  • Hyperfine, Inc. Reports Third Quarter 2026 Financial Results

  • Sysmex (OTCMKTS:SSMXY) vs. Hyperfine (NASDAQ:HYPR) Critical Analysis

  • Hyperfine to Participate in Jefferies London and BTIG Tech-Enabled Healthcare Conferences

  • Hyperfine Advances International Swoop System Model 2 Rollout and Highlights the Role of Portable MRI in Brain Health Awareness

  • Hyperfine (NASDAQ: HYPR) revenue tops cash burn as it secures $40 million loan

  • Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026

  • Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million

  • Neuralink Stock: How to Invest Before the IPO

  • Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets

  • MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award

  • Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

  • Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference

  • Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

  • Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

  • Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

  • Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

  • Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript

  • Hyperfine Q2 Earnings Call Highlights